Sun Pharma Proposes 11.75‑billion‑dollar Acquisition of US‑based Organon
New Delhi: India’s pharmacy industry is achieving new heights in the US market. India’s leading pharmaceutical company Sun Pharma has proposed 11.75‑billion‑dollar acquisition of US‑based Organon. Sharing a news report, former NITI Aayog CEO Amitabh Kant writes on social media platform X, “Sun Pharma’s proposed 11.75‑billion‑dollar acquisition of US‑based Organon is a coming‑of‑age moment for Indian pharma on the global stage.” Amitabh Kant further writes, “It will put India’s largest drugmaker firmly within the global top 25, with exposure to women’s health and biosimilars across roughly 140 countries. Beyond scaling
